{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:59:27Z","timestamp":1781593167567,"version":"3.54.5"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T00:00:00Z","timestamp":1557360000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Australian Self-Medication Industry"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s40273-019-00804-6","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T02:03:47Z","timestamp":1557367427000},"page":"1049-1064","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Is Reclassification of the Oral Contraceptive Pill from Prescription to Pharmacist-Only Cost Effective? Application of an Economic Evaluation Approach to Regulatory Decisions"],"prefix":"10.1007","volume":"37","author":[{"given":"Mutsa","family":"Gumbie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2137-0962","authenticated-orcid":false,"given":"Bonny","family":"Parkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Gauld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Mumford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,9]]},"reference":[{"issue":"1","key":"804_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1728-4465.2008.00148.x","volume":"39","author":"J Gipson","year":"2008","unstructured":"Gipson J, Koenig M, Hindin M. The effects of unintended pregnancy on infant, child, and parental health: a review of the literature. Stud Fam Plan. 2008;39(1):18\u201338.","journal-title":"Stud Fam Plan"},{"key":"804_CR2","volume-title":"One in three: the case for wanted and welcomed pregnancy","author":"National Campaign to Prevent Teen Pregnancy","year":"2007","unstructured":"National Campaign to Prevent Teen Pregnancy. One in three: the case for wanted and welcomed pregnancy. Washington, DC: National Campaign to Prevent Teen Pregnancy; 2007."},{"key":"804_CR3","first-page":"1","volume":"25","author":"A Chandra","year":"2005","unstructured":"Chandra A, Martinez G, Mosher W, et al. Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. Vital Health Stat 23. 2005;25:1\u2013160.","journal-title":"Vital Health Stat 23"},{"issue":"3","key":"804_CR4","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1097\/01.AOG.0000255666.78427.c5","volume":"109","author":"P Mohllajee","year":"2007","unstructured":"Mohllajee P, Curtis M, Morrow A, et al. Pregnancy intention and its relationship to birth and maternal outcomes. Obstet Gynecol. 2007;109(3):678\u201386.","journal-title":"Obstet Gynecol"},{"issue":"5","key":"804_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2307\/2991608","volume":"30","author":"K Kost","year":"1998","unstructured":"Kost K, Landry D, Darroch J. The effects of pregnancy planning status on birth outcomes and infant care. Fam Plan Perspect. 1998;30(5):223\u201330.","journal-title":"Fam Plan Perspect"},{"issue":"2","key":"804_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/1753-6405.12461","volume":"40","author":"H Rowe","year":"2016","unstructured":"Rowe H, Holton S, Kirkman M, et al. Prevalence and distribution of unintended pregnancy: the Understanding Fertility Management in Australia National Survey. Aust N Z J Public Health. 2016;40(2):104\u20139.","journal-title":"Aust N Z J Public Health"},{"key":"804_CR7","volume-title":"The Household, Income and Labour Dynamics in Australia (HILDA) data","author":"Melbourne Institute of Applied Economic Social Research","year":"2015","unstructured":"Melbourne Institute of Applied Economic Social Research. The Household, Income and Labour Dynamics in Australia (HILDA) data. Melbourne: Melbourne Institute of Applied Economic and Social Research; 2015."},{"issue":"6","key":"804_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.contraception.2006.07.006","volume":"74","author":"S Landau","year":"2006","unstructured":"Landau S, Tapias M, McGhee B. Birth control within reach: a national survey on women\u2019s attitudes toward and interest in pharmacy access to hormonal contraception. Contraception. 2006;74(6):463\u201370.","journal-title":"Contraception"},{"issue":"3","key":"804_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/AOG.0b013e31820afc46","volume":"117","author":"J Potter","year":"2011","unstructured":"Potter J, McKinnon S, Hopkins K, et al. Continuation of prescribed compared with over-the-counter oral contraceptives. Obstet Gynecol. 2011;117(3):551\u20137.","journal-title":"Obstet Gynecol"},{"key":"804_CR10","volume-title":"Interim decisions and reasons for decisions by delegates of the Secretary to the Department of Health, June 2015","author":"Therapeutic Goods Administration","year":"2015","unstructured":"Therapeutic Goods Administration. Interim decisions and reasons for decisions by delegates of the Secretary to the Department of Health, June 2015. Canberra: Therapeutic Goods Administration; 2015."},{"key":"804_CR11","volume-title":"Oral contraception recommendation made","author":"New Zealand Medicines and Medical Devices Safety Authority","year":"2017","unstructured":"New Zealand Medicines and Medical Devices Safety Authority. Oral contraception recommendation made. Wellington, New Zealand: New Zealand Medicines and Medical Devices Safety Authority; 2017."},{"issue":"1","key":"804_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.contraception.2012.11.021","volume":"88","author":"K Grindlay","year":"2013","unstructured":"Grindlay K, Burns B, Grossman D. Prescription requirements and over-the-counter access to oral contraceptives: a global review. Contraception. 2013;88(1):91\u20136.","journal-title":"Contraception"},{"issue":"1","key":"804_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/AOG.0000000000001474","volume":"128","author":"M Rodriguez","year":"2016","unstructured":"Rodriguez M, Anderson L, Edelman A. Prescription of hormonal contraception by pharmacists in Oregon: implementation of house bill 2879. Obstet Gynecol. 2016;128(1):168\u201370.","journal-title":"Obstet Gynecol"},{"key":"804_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/S1042-0991(15)30225-5","volume-title":"Oregon pharmacists may now prescribe hormonal contraceptives","author":"L Bonner","year":"2015","unstructured":"Bonner L. Oregon pharmacists may now prescribe hormonal contraceptives. American Pharmacists Association: Washington DC; 2015."},{"issue":"3","key":"804_CR15","doi-asserted-by":"publisher","first-page":"e0119011","DOI":"10.1371\/journal.pone.0119011","volume":"10","author":"N Gauld","year":"2015","unstructured":"Gauld N, Kelly F, Emmerton L, et al. Widening consumer access to medicines: a comparison of prescription to non-prescription medicine switch in Australia and New Zealand. PLoS One. 2015;10(3):e0119011.","journal-title":"PLoS One"},{"key":"804_CR16","doi-asserted-by":"publisher","DOI":"10.1211\/cp.2017.20202645","author":"N Gauld","year":"2017","unstructured":"Gauld N. Why the resurgence of OTC reclassifications in the UK is a good thing. Clin Pharm. 2017. \n                    https:\/\/doi.org\/10.1211\/cp.2017.20202645\n                    \n                  .","journal-title":"Clin Pharm."},{"issue":"6","key":"804_CR17","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/clpt.2011.231","volume":"90","author":"E Brass","year":"2011","unstructured":"Brass E, Lofstedt R, Renn O. Improving the decision-making process for nonprescription drugs: a framework for benefit-risk assessment. Clin Pharmacol Ther. 2011;90(6):791\u2013803.","journal-title":"Clin Pharmacol Ther"},{"key":"804_CR18","volume-title":"Minutes of the 57th meeting of the Medicines Classification Committee held in Wellington on Tuesday 1 November 2016 at 9:30\u00a0a.m.","author":"Medsafe","year":"2017","unstructured":"Medsafe. Minutes of the 57th meeting of the Medicines Classification Committee held in Wellington on Tuesday 1 November 2016 at 9:30\u00a0a.m. Wellington, New Zealand: New Zealand Medicines and Medical Devices Safety Authority; 2017."},{"key":"804_CR19","unstructured":"Pharmaceutical Society of New Zealand Incorporated. Practice guidelines: pharmacist-supply of selected oral contraceptives (SOCs). Wellington: Pharmaceutical Society of New Zealand Incorporated. \n                    https:\/\/www.psnz.org.nz\/Folder?Action=View%20File%26Folder_id=169%26File=Pharmacist%20SOC%20Guidelines%202018.pdf\n                    \n                  . Accessed 28 Mar 2019."},{"key":"804_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1300\/J063v11n03_09","volume":"11","author":"M Zhu","year":"2002","unstructured":"Zhu M, Wertheimer A, Field R. The financial impact of over-the-counter availability of oral contraceptive pills. J Res Pharm Econ. 2002;11:125\u201342.","journal-title":"J Res Pharm Econ"},{"issue":"5","key":"804_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.contraception.2015.01.010","volume":"91","author":"D Foster","year":"2015","unstructured":"Foster D, Biggs M, Phillips K, et al. Potential public sector cost-savings from over-the-counter access to oral contraceptives. Contraception. 2015;91(5):373\u20139.","journal-title":"Contraception"},{"key":"804_CR22","unstructured":"Koslow S, West A, Xu C, et al. The value of OTC medicines in Australia. Macquarie University: Sydney; 2014."},{"key":"804_CR23","volume-title":"Making birth control more accessible to women: a cost-benefit analysis of over-the-counter oral contraceptives. Institute for Women\u2019s Policy Research, publication #B236","author":"H Mead","year":"2001","unstructured":"Mead H. Making birth control more accessible to women: a cost-benefit analysis of over-the-counter oral contraceptives. Institute for Women\u2019s Policy Research, publication #B236. Washington: Institute for Women\u2019s Policy Research; 2001."},{"issue":"6","key":"804_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.contraception.2004.03.008","volume":"69","author":"F Sonnenberg","year":"2004","unstructured":"Sonnenberg F, Burkman R, Hagerty C, et al. Costs and net health effects of contraceptive methods. Contraception. 2004;69(6):447\u201359.","journal-title":"Contraception"},{"issue":"5","key":"804_CR25","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1071\/SH14105","volume":"11","author":"C Rissel","year":"2014","unstructured":"Rissel C, Badcock P, Smith A, et al. Heterosexual experience and recent heterosexual encounters among Australian adults: the Second Australian Study of Health and Relationships. Sex Health. 2014;11(5):416\u201326.","journal-title":"Sex Health"},{"issue":"1","key":"804_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/00324720701804207","volume":"62","author":"H Leridon","year":"2008","unstructured":"Leridon H. A new estimate of permanent sterility by age: sterility defined as the inability to conceive. Popul Stud (Camb). 2008;62(1):15\u201324.","journal-title":"Popul Stud (Camb)"},{"key":"804_CR27","volume-title":"Guidance for provision of a pharmacist only medicine: emergency contraception","author":"Pharmaceutical Society of Australia","year":"2018","unstructured":"Pharmaceutical Society of Australia. Guidance for provision of a pharmacist only medicine: emergency contraception. Canberra: Pharmaceutical Society of Australia; 2018."},{"issue":"5","key":"804_CR28","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.contraception.2006.12.019","volume":"75","author":"J Dinger","year":"2007","unstructured":"Dinger J, Heinemann L, K\u00fchl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75(5):344\u201354.","journal-title":"Contraception"},{"key":"804_CR29","volume-title":"Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee","author":"Pharmaceutical Benefits Advisory Committee","year":"2016","unstructured":"Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Australian Government Department of Health; 2016."},{"issue":"2","key":"804_CR30","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jval.2013.02.010","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health. 2013;16(2):e1\u20135.","journal-title":"Value Health"},{"issue":"4","key":"804_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro Ramos I, van Voorn GA, et al. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349\u201361.","journal-title":"Pharmacoeconomics"},{"key":"804_CR32","volume-title":"Births Australia 1997","author":"Australian Bureau of Statistics","year":"1997","unstructured":"Australian Bureau of Statistics. Births Australia 1997. Canberra: Australian Bureau of Statistics; 1997."},{"issue":"2","key":"804_CR33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2307\/2991641","volume":"31","author":"J Trussell","year":"1999","unstructured":"Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plan Perspect. 1999;31(2):64\u201393.","journal-title":"Fam Plan Perspect"},{"issue":"5","key":"804_CR34","doi-asserted-by":"publisher","first-page":"662.e1","DOI":"10.1016\/j.ajog.2015.08.001","volume":"213","author":"JT Diedrich","year":"2015","unstructured":"Diedrich JT, Zhao Q, Madden T, et al. Three-year continuation of reversible contraception. Am J Obstet Gynecol. 2015;213(5):662.e1\u20138.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"804_CR35","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2105\/AJPH.2009.179887","volume":"100","author":"J Potter","year":"2010","unstructured":"Potter J, White K, Hopkins K, et al. Clinic versus over-the-counter access to oral contraception: choices women make along the US-Mexico border. Am J Public Health. 2010;100(6):1130\u20136.","journal-title":"Am J Public Health"},{"key":"804_CR36","volume-title":"Combined oral contraceptive (COC) checklist","author":"Green Cross Health NGL","year":"2017","unstructured":"Green Cross Health NGL. Combined oral contraceptive (COC) checklist. Wellington: Pharmaceutical Society of New Zealand; 2017."},{"issue":"2","key":"804_CR37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/jfprhc-2012-100304","volume":"39","author":"J Parsons","year":"2013","unstructured":"Parsons J, Adams C, Aziz N, et al. Evaluation of a community pharmacy delivered oral contraception service. J Fam Plan Reprod Health Care. 2013;39(2):97\u2013101.","journal-title":"J Fam Plan Reprod Health Care"},{"key":"804_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007541.pub3","author":"DA Grimes","year":"2013","unstructured":"Grimes DA, Lopez LM, O\u2019Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Database Syst Rev. 2013. \n                    https:\/\/doi.org\/10.1002\/14651858.CD007541.pub3\n                    \n                  .","journal-title":"Cochrane Database Syst Rev."},{"key":"804_CR39","volume-title":"Maternal deaths in Australia 2012\u20132014. Cat. no. PER 92","author":"Australian Institute of Health and Welfare","year":"2017","unstructured":"Australian Institute of Health and Welfare. Maternal deaths in Australia 2012\u20132014. Cat. no. PER 92. Canberra: Australian Institute of Health and Welfare; 2017."},{"issue":"1","key":"804_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/AOG.0b013e318291c235","volume":"122","author":"LJ Havrilesky","year":"2013","unstructured":"Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol. 2013;122(1):139\u201347.","journal-title":"Obstet Gynecol"},{"key":"804_CR41","volume-title":"2017 Australian cancer incidence and mortality (ACIM) books: ovarian cancer","author":"Australian Institute of Health and Welfare","year":"2017","unstructured":"Australian Institute of Health and Welfare. 2017 Australian cancer incidence and mortality (ACIM) books: ovarian cancer. Canberra: Australian Institute of Health and Welfare; 2017."},{"key":"804_CR42","volume-title":"Ovarian cancer in Australia: an overview, 2010. Cancer series no. 52. Cat. no. CAN 48","author":"Australian Institute of Health and Welfare and National Breast and Ovarian Cancer Centre","year":"2010","unstructured":"Australian Institute of Health and Welfare and National Breast and Ovarian Cancer Centre. Ovarian cancer in Australia: an overview, 2010. Cancer series no. 52. Cat. no. CAN 48. Canberra: Australian Institute of Health and Welfare; 2010."},{"issue":"6","key":"804_CR43","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/j.1471-0528.2012.03298.x","volume":"119","author":"S Wilailak","year":"2012","unstructured":"Wilailak S, Vipupinyo C, Suraseranivong V, et al. Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case\u2013control study. BJOG. 2012;119(6):672\u20137.","journal-title":"BJOG"},{"issue":"9609","key":"804_CR44","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","volume":"371","author":"Collaborative Group on Epidemiological Studies of Ovarian Cancer","year":"2008","unstructured":"Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23\u2008257 women with ovarian cancer and 87\u2008303 controls. Lancet. 2008;371(9609):303\u201314.","journal-title":"Lancet"},{"issue":"2","key":"804_CR45","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ygyno.2006.03.046","volume":"103","author":"G Maxwell","year":"2006","unstructured":"Maxwell G, Schildkraut J, Calingaert B, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol. 2006;103(2):535\u201340.","journal-title":"Gynecol Oncol"},{"key":"804_CR46","volume-title":"Life tables, states, territories and Australia, 2013\u20132015, Cat. No. 3302.0.55.001","author":"Australian Bureau of Statistics","year":"2015","unstructured":"Australian Bureau of Statistics. Life tables, states, territories and Australia, 2013\u20132015, Cat. No. 3302.0.55.001. Canberra: Australian Bureau of Statistics; 2015."},{"issue":"12","key":"804_CR47","first-page":"1499","volume":"82","author":"Barr N Grossman","year":"2010","unstructured":"Grossman Barr N. Managing adverse effects of hormonal contraceptives. Am Fam Phys. 2010;82(12):1499\u2013506.","journal-title":"Am Fam Phys"},{"issue":"11","key":"804_CR48","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1001\/jamapsychiatry.2016.2387","volume":"73","author":"C Skovlund","year":"2016","unstructured":"Skovlund C, Morch L, Kessing L. Association of hormonal contraception with depression. JAMA Psychiatry. 2016;73(11):1154\u201362.","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"804_CR49","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.contraception.2006.01.001","volume":"73","author":"S Jick","year":"2006","unstructured":"Jick S, Kaye J, Russmann S, et al. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35\u00a0microg of ethinyl estradiol. Contraception. 2006;73(3):223\u20138.","journal-title":"Contraception"},{"key":"804_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011054","author":"RE Roach","year":"2015","unstructured":"Roach RE, Helmerhorst FM, Lijfering WM, Algra A, Dekkers OM. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015. \n                    https:\/\/doi.org\/10.1002\/14651858.CD011054\n                    \n                  .","journal-title":"Cochrane Database Syst Rev."},{"issue":"7621","key":"804_CR51","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/bmj.39289.649410.55","volume":"335","author":"P Hannaford","year":"2007","unstructured":"Hannaford P, Selvaraj S, Elliott A, et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner\u2019s oral contraception study. BMJ. 2007;335(7621):651.","journal-title":"BMJ"},{"key":"804_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003255","author":"SC Weller","year":"2002","unstructured":"Weller SC, Davis-Beaty K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002. \n                    https:\/\/doi.org\/10.1002\/14651858.CD003255\n                    \n                  .","journal-title":"Cochrane Database Syst Rev."},{"issue":"6","key":"804_CR53","first-page":"454","volume":"82","author":"KK Holmes","year":"2004","unstructured":"Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ. 2004;82(6):454\u201361.","journal-title":"Bull World Health Organ"},{"key":"804_CR54","volume-title":"Evaluation of the national human papillomavirus vaccination program","author":"National Centre for Immunisation Research and Surveillance","year":"2014","unstructured":"National Centre for Immunisation Research and Surveillance. Evaluation of the national human papillomavirus vaccination program. Sydney: National Centre for Immunisation Research and Surveillance (NICRS); 2014."},{"key":"804_CR55","volume-title":"Notifications of a selected disease by age group and sex","author":"National Notifiable Diseases Surveillance System","year":"2016","unstructured":"National Notifiable Diseases Surveillance System. Notifications of a selected disease by age group and sex. Canberra: Australian Government Department of Health; 2016."},{"key":"804_CR56","volume-title":"Reproductive and sexual health in Australia","author":"Family Planning NSW","year":"2013","unstructured":"Family Planning NSW. Reproductive and sexual health in Australia. Sydney: Family Planning NSW; 2013."},{"issue":"9783","key":"804_CR57","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/S0140-6736(11)60551-5","volume":"377","author":"J Brotherton","year":"2011","unstructured":"Brotherton J, Fridman M, May C, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377(9783):2085\u201392.","journal-title":"Lancet"},{"issue":"1","key":"804_CR58","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12955-016-0537-0","volume":"14","author":"N McCaffrey","year":"2016","unstructured":"McCaffrey N, Kaambwa B, Currow DC, et al. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms. Health Qual Life Outcomes. 2016;14(1):133.","journal-title":"Health Qual Life Outcomes"},{"issue":"12","key":"804_CR59","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1001\/jamainternmed.2013.563","volume":"173","author":"K Hogg","year":"2013","unstructured":"Hogg K, Kimpton M, Carrier M, et al. Estimating quality of life in acute venous thrombosis. JAMA Intern Med. 2013;173(12):1067\u201372.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"804_CR60","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1046\/j.1440-1614.2003.01189.x","volume":"37","author":"G Hawthorne","year":"2003","unstructured":"Hawthorne G, Cheok F, Goldney R, et al. The excess cost of depression in South Australia: a population-based study. Aust N Z J Psychiatry. 2003;37(3):362\u201373.","journal-title":"Aust N Z J Psychiatry"},{"key":"804_CR61","unstructured":"Ara R, Brazier J. Health related quality of life by age, gender and history of cardiovascular disease: results from the Health Survey for England. HEDS discussion paper 09\/12. Sheffield: The University of Sheffield; 2009."},{"key":"804_CR62","volume-title":"Vaccines for the 21st century: a tool for decision making","author":"Institute of Medicine","year":"1999","unstructured":"Institute of Medicine. Vaccines for the 21st century: a tool for decision making. Washington, DC: National Academy Press; 1999."},{"issue":"11","key":"804_CR63","doi-asserted-by":"publisher","first-page":"e712","DOI":"10.1016\/S2214-109X(15)00069-8","volume":"3","author":"J Salomon","year":"2015","unstructured":"Salomon J, Haagsma J, Davis A, et al. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health. 2015;3(11):e712\u201323.","journal-title":"Lancet Glob Health"},{"key":"804_CR64","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1186\/1756-0500-7-899","volume":"7","author":"L Simonella","year":"2014","unstructured":"Simonella L, Howard K, Canfell K. A survey of population-based utility scores for cervical cancer prevention. BMC Res Notes. 2014;7:899.","journal-title":"BMC Res Notes"},{"issue":"5","key":"804_CR65","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/IGC.0b013e3181dbd13f","volume":"20","author":"LG Gordon","year":"2010","unstructured":"Gordon LG, Scuffham PA, Beesley VL, et al. Medical costs and outcomes for Australian women with ovarian cancer: a patient-level analysis over 2.5\u00a0years. Int J Gynecol Cancer. 2010;20(5):757\u201365.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"804_CR66","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/QAI.0b013e3182973966","volume":"64","author":"P Farnham","year":"2013","unstructured":"Farnham P, Gopalappa C, Sansom S, et al. Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. J Acquir Immune Defic Syndr. 2013;64(2):183\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"804_CR67","volume-title":"Schedule of Pharmaceutical Benefits, effective 1 December 2015\u201331 December 2015","author":"Australian Government Department of Health","year":"2015","unstructured":"Australian Government Department of Health. Schedule of Pharmaceutical Benefits, effective 1 December 2015\u201331 December 2015. Canberra: Australian Government Department of Health; 2015."},{"key":"804_CR68","first-page":"38","volume-title":"General practice activity in Australia 2014\u201315: general practice series no","author":"H Britt","year":"2015","unstructured":"Britt H, Miller G, Henderson J, et al. General practice activity in Australia 2014\u201315: general practice series no. 38. Sydney: Sydney University Press; 2015."},{"issue":"9907","key":"804_CR69","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/S0140-6736(13)62035-8","volume":"382","author":"C Mercer","year":"2013","unstructured":"Mercer C, Tanton C, Prah P, et al. Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet. 2013;382(9907):1781\u201394.","journal-title":"Lancet"},{"key":"804_CR70","volume-title":"Implanon NXT, product information","author":"Therapeutic Goods Administration","year":"2016","unstructured":"Therapeutic Goods Administration. Implanon NXT, product information. Canberra: Therapeutic Goods Administration; 2016."},{"key":"804_CR71","volume-title":"Depo Provera, product information","author":"Therapeutic Goods Administration","year":"2017","unstructured":"Therapeutic Goods Administration. Depo Provera, product information. Canberra: Therapeutic Goods Administration; 2017."},{"key":"804_CR72","volume-title":"Hormone-releasing IUD (Mirena)","author":"NSW Family Planning","year":"2017","unstructured":"Family Planning NSW. Hormone-releasing IUD (Mirena). Ashfield, Sydney: Family Planning NSW; 2017."},{"key":"804_CR73","volume-title":"Copper IUD","author":"NSW Family Planning","year":"2017","unstructured":"Family Planning NSW. Copper IUD. Ashfield, Sydney: Family Planning NSW; 2017."},{"key":"804_CR74","volume-title":"NuvaRing, product information","author":"Therapeutic Goods Administration","year":"2017","unstructured":"Therapeutic Goods Administration. NuvaRing, product information. Canberra: Therapeutic Goods Administration; 2017."},{"key":"804_CR75","volume-title":"Single-size contraceptive barrier device, CAYA diaphragm, fact sheet","author":"NSW Family Planning","year":"2017","unstructured":"Family Planning NSW. Single-size contraceptive barrier device, CAYA diaphragm, fact sheet. Ashfield, Sydney: Family Planning NSW; 2017."},{"issue":"3","key":"804_CR76","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s11096-009-9289-9","volume":"31","author":"H Puspitasari","year":"2009","unstructured":"Puspitasari H, Aslani P, Krass I. How do Australian metropolitan and rural pharmacists counsel consumers with prescriptions? Pharm World Sci. 2009;31(3):394\u2013405.","journal-title":"Pharm World Sci"},{"issue":"4","key":"804_CR77","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/head.12308","volume":"54","author":"P Mathew","year":"2014","unstructured":"Mathew P, Pavlovic J, Lettich A, et al. Education and decision making at the time of triptan prescribing: patient expectations vs actual practice. Headache. 2014;54(4):698\u2013708.","journal-title":"Headache"},{"key":"804_CR78","volume-title":"Evaluation of oral contraception in community pharmacy pilot in Southwark and Lambeth","author":"National Health Service South East London","year":"2012","unstructured":"National Health Service South East London. Evaluation of oral contraception in community pharmacy pilot in Southwark and Lambeth. London: National Health Service UK; 2012."},{"key":"804_CR79","unstructured":"Personal correspondence from S Vasan, Pharmaceutical Society of New Zealand; 2018."},{"key":"804_CR80","volume-title":"Exchange rates","author":"Reserve Bank of Australia","year":"2019","unstructured":"Reserve Bank of Australia. Exchange rates. Sydney: Reserve Bank of Australia; 2019."},{"key":"804_CR81","volume-title":"The economic impact of stroke in Australia","author":"Deloitte Access Economics","year":"2013","unstructured":"Deloitte Access Economics. The economic impact of stroke in Australia. Sydney: Deloitte; 2013."},{"key":"804_CR82","volume-title":"Health expenditure Australia 2014\u201315, AIHW cat. no. HWE 67","author":"Australian Institute of Health and Welfare","year":"2016","unstructured":"Australian Institute of Health and Welfare. Health expenditure Australia 2014\u201315, AIHW cat. no. HWE 67. Canberra: Australian Institute of Health and Welfare; 2016."},{"issue":"8","key":"804_CR83","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2165\/11536350-000000000-00000","volume":"30","author":"L Ioannides-Demos","year":"2010","unstructured":"Ioannides-Demos L, Makarounas-Kirchmann K, Ashton E, et al. Cost of myocardial infarction to the Australian community: a prospective, multicentre survey. Clin Drug Investig. 2010;30(8):533\u201343.","journal-title":"Clin Drug Investig"},{"issue":"6","key":"804_CR84","first-page":"404","volume":"43","author":"B Garth","year":"2014","unstructured":"Garth B, Temple-Smith M, Clark M, et al. \u2018Your lack of organisation doesn\u2019t constitute our emergency\u2019: repeat prescription management in general practice. Aust Fam Phys. 2014;43(6):404\u20138.","journal-title":"Aust Fam Phys"},{"issue":"5","key":"804_CR85","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.contraception.2011.01.021","volume":"83","author":"J Trussell","year":"2011","unstructured":"Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397\u2013404.","journal-title":"Contraception"},{"key":"804_CR86","volume-title":"Final appraisal determination: routine antenatal anti-D prophylaxis for women who are RhD negative (review of technology appraisal guidance 41)","author":"National Institute for Health and Clinical Excellence","year":"2008","unstructured":"National Institute for Health and Clinical Excellence. Final appraisal determination: routine antenatal anti-D prophylaxis for women who are RhD negative (review of technology appraisal guidance 41). London: National Institute for Health and Clinical Excellence; 2008."},{"issue":"2","key":"804_CR87","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40273-017-0585-2","volume":"36","author":"LC Edney","year":"2018","unstructured":"Edney LC, Afzali HHA, Cheng TC, et al. Estimating the reference incremental cost-effectiveness ratio for the Australian health system. Pharmacoeconomics. 2018;36(2):239\u201352.","journal-title":"Pharmacoeconomics"},{"key":"804_CR88","volume-title":"Births Australia, 2016, Cat. no. 3301.0","author":"Australian Bureau of Statistics","year":"2016","unstructured":"Australian Bureau of Statistics. Births Australia, 2016, Cat. no. 3301.0. Canberra: Australian Bureau of Statistics; 2016."},{"key":"804_CR89","unstructured":"National health (continued dispensing) determination 2012. Canberra: Commonwealth Government of Australia; 2012."},{"key":"804_CR90","volume-title":"Scheduling policy framework for medicines and chemicals. Version 1.0","author":"Australian Health Ministers\u2019 Advisory Council","year":"2018","unstructured":"Australian Health Ministers\u2019 Advisory Council. Scheduling policy framework for medicines and chemicals. Version 1.0. Canberra: Therapeutic Goods Administration; 2018."},{"key":"804_CR91","volume-title":"Consensus statement: reducing unintended pregnancy for Australian women through increased access to long-acting reversible contraceptive methods","author":"D Batesman","year":"2017","unstructured":"Batesman D, Brassil A, Calabretto H, et al. Consensus statement: reducing unintended pregnancy for Australian women through increased access to long-acting reversible contraceptive methods. Deakin: Australian Healthcare and Hospitals Association; 2017."},{"issue":"7","key":"804_CR92","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1177\/0272989X15583845","volume":"35","author":"JD Goldhaber-Fiebert","year":"2015","unstructured":"Goldhaber-Fiebert JD, Brandeau ML. Evaluating cost-effectiveness of interventions that affect fertility and childbearing: how health effects are measured matters. Med Decis Mak. 2015;35(7):818\u201346.","journal-title":"Med Decis Mak"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00804-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-019-00804-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00804-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T23:10:12Z","timestamp":1588893012000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-019-00804-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,9]]},"references-count":92,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1007\/s40273-019-00804-6","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,9]]},"assertion":[{"value":"9 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by a grant from the Australian Self-Medication Industry. The funding agreement ensured the authors\u2019 independence in designing the economic evaluation, its inputs or the writing of the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mutsa Gumbie, Bonny Parkinson, Henry Cutler and Virginia Mumford have no conflicts of interest that are directly relevant to the content of this article. Natalie Gauld has received consulting fees from Green Cross Health for reclassifying oral contraceptives in New Zealand, has received an honorarium and expenses for attending a meeting for HRA Pharma, is a Board Member of the Pharmaceutical Society of New Zealand, and receives consulting fees, research funding and speaker\u2019s fees relating to reclassification.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"BP and HC conceived the idea for the study. MG and BP developed the economic model and conducted the data analysis. NG and VM provided advice on parameter inputs. MG drafted the initial paper. All authors were involved in the interpretation of the results and revision of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"All parameter inputs and the economic model are available in the ESM.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}